Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Interest & Investment Income: 2013-2020

Historic Interest & Investment Income for ImmunityBio (IBRX) over the last 8 years, with Dec 2020 value amounting to $1.2 million.

  • ImmunityBio's Interest & Investment Income fell 67.16% to $112,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $9.9 million, marking a year-over-year increase of 757.89%. This contributed to the annual value of $1.2 million for FY2020, which is 24.95% down from last year.
  • Latest data reveals that ImmunityBio reported Interest & Investment Income of $1.2 million as of FY2020, which was down 24.95% from $1.6 million recorded in FY2019.
  • In the past 5 years, ImmunityBio's Interest & Investment Income registered a high of $5.2 million during FY2016, and its lowest value of $1.2 million during FY2020.
  • Its 3-year average for Interest & Investment Income is $1.7 million, with a median of $1.6 million in 2019.
  • As far as peak fluctuations go, ImmunityBio's Interest & Investment Income skyrocketed by 72.96% in 2016, and later crashed by 45.16% in 2018.
  • Over the past 5 years, ImmunityBio's Interest & Investment Income (Yearly) stood at $5.2 million in 2016, then dropped by 18.25% to $4.2 million in 2017, then crashed by 45.16% to $2.3 million in 2018, then declined by 29.09% to $1.6 million in 2019, then fell by 24.95% to $1.2 million in 2020.